ORXOF Stock Chart & Stats
$3.82
-$0.42(-28.00%)
At close: 4:00 PM EDT
$3.82
-$0.42(-28.00%)
Day’s Range― - ―
52-Week Range$1.80 - $4.09
Previous CloseN/A
Volume3.00K
Average Volume (3M)66.00
Market Cap
$82.45M
Enterprise Value$358.47M
Total Cash (Recent Filing)$386.20M
Total Debt (Recent Filing)$7.00M
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Jul 16, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.10
Shares Outstanding35,127,056
10 Day Avg. Volume0
30 Day Avg. Volume66
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.12
Price to Sales (P/S)40.09
P/FCF Ratio6.02
Enterprise Value/Market Cap4.35
Enterprise Value/Revenue1.46
Enterprise Value/Gross Profit-1.93
Enterprise Value/Ebitda-0.98
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.77
Revenue Forecast (FY)$2.72M
Bulls Say, Bears Say
Bulls Say
Improved Cash GenerationA sustained TTM operating and free cash flow of roughly $117M materially improves the firm's ability to fund operations, R&D, and commercial efforts without immediate external financing. Durable positive cash flow lowers short-term liquidity risk and enables strategic reinvestment if maintained.
Low LeverageVery low trailing leverage (debt-to-equity ~0.02) provides financial flexibility, reducing interest burden and giving the company capacity to absorb shocks or pursue partnerships. Over a medium horizon this supports investment discretion and lowers refinancing risk versus highly leveraged peers.
Specialty Pharma Focus & U.S. OUD PresenceConcentration on specialty pharmaceuticals (notably OUD treatment) and investment in digital therapeutics creates defensible niches with recurring prescription demand and higher reimbursement barriers. This focused model supports durable revenue channels and diversification via partnerships and licensing.
Bears Say
Steep Revenue DeclineA greater-than-50% TTM revenue contraction is a structural red flag: it reduces operating leverage, shrinks addressable cash flow from existing operations, and stresses the business model. Without clear drivers for revenue recovery, sustaining margins and funding future product investment becomes harder.
Persistently Negative ProfitabilityNegative gross, operating, and net margins imply the core business does not yet cover costs. Even with positive cash flow, ongoing losses point to high operating expenses or one-time charges that can erode capital over time unless margins are restored through revenue growth or structural cost reductions.
Historical Balance Sheet VolatilityThe company's balance sheet has shown past instability, including negative equity and high leverage in recent years. That track record raises medium-term risk of recurrence, may constrain access to favorable financing, and implies governance or structural issues that could re-emerge under stress.
Orexo AB News
ORXOF FAQ
What was Orexo AB’s price range in the past 12 months?
Orexo AB lowest stock price was $1.80 and its highest was $4.09 in the past 12 months.
What is Orexo AB’s market cap?
Orexo AB’s market cap is $82.45M.
When is Orexo AB’s upcoming earnings report date?
Orexo AB’s upcoming earnings report date is Jul 16, 2026 which is in 6 days.
How were Orexo AB’s earnings last quarter?
Orexo AB released its earnings results on Apr 28, 2026. The company reported -$0.311 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.311.
Is Orexo AB overvalued?
According to Wall Street analysts Orexo AB’s price is currently Overvalued.
Does Orexo AB pay dividends?
Orexo AB does not currently pay dividends.
What is Orexo AB’s EPS estimate?
Orexo AB’s EPS estimate is -0.17.
How many shares outstanding does Orexo AB have?
Orexo AB has 35,127,056 shares outstanding.
What happened to Orexo AB’s price movement after its last earnings report?
Orexo AB reported an EPS of -$0.311 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.667%.
Which hedge fund is a major shareholder of Orexo AB?
Currently, no hedge funds are holding shares in ORXOF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis. Its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
ORXOF Company Deck
ORXOF Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicates a materially improved financial position driven by the successful sale of ZUBSOLV U.S., resulting in strong cash proceeds (SEK 814 million net) and a net cash position (SEK 429.2 million), while allowing a strategic refocus on the AmorphOX platform and prioritized R&D milestones (OX640 pivotal trial planned Q4, OX390 in‑vivo starting Q1, IZIPRY filing target Q3/2026). However, near-term challenges remain including weak continued-operations revenue (SEK 3.3 million), negative continued-ops EBITDA (SEK -70 million for Q4), impairments (MODIA SEK 22 million), outstanding DOJ investigation risk, bond covenant remediation/possible redemption, restructuring costs in 2026, and reliance on partnerships and BARDA funding to sustain and accelerate development. Overall, the positives from the transaction, cash position, meeting 2025 metrics, and clear strategic direction outweigh the operational and legal headwinds, positioning Orexo to focus on technology-driven R&D growth but with execution and financing risks to monitor.View all ORXOF earnings summariesTechnical Analysis
AlzeCure Pharma AB
―
Klaria Pharma Holding AB
―
Nanexa AB
―
Enzymatica AB
―
Enorama Pharma AB
―
Ownership Overview
―
Insiders
0.05% Mutual Funds
― Other Institutional Investors
99.95% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---